The World Bank accused of deception and medical malpractice in malaria treatment

April 24, 2006

In a Viewpoint published online by The Lancet on Africa Malaria Day (April 25), a group of public health experts claim that the World Bank has published false financial and statistical accounts and wasted money on ineffective medicines in malaria treatment. Also published online today is a response from The World Bank, which argues that the authors' claims are unfounded. An Editorial by The Lancet considers the challenge lying ahead for new World Bank president, Paul Wolfowitz.

The World Bank has an annual budget of US $ 20 billion and is the largest foreign aid organisation with a mission to reduce poverty. Malaria kills over 1 million--mainly African children--yearly and causes vast poverty. In their Viewpoint Amir Attaran (University of Ottawa, Ontario, Canada) and colleagues argue that the Bank's new Global Strategy & Booster Program for controlling malaria in 2005-10 continues the organisation's history of neglect for the disease. The authors' allege that since 2000, the Bank:Attaran and colleagues recommend that since the Bank has downsized all its malaria staff and has little expertise left, it wind down its malaria projects and allocate US$1 billion to other institutions, such as the Global Fund for AIDS, Tuberculosis and Malaria (GFATM).

In response, the World Bank's Jean-Louis Sarbib and colleagues acknowledge that the institution should have done more in the past to intensify its anti-malaria efforts, but nonetheless take exception to the charges. Citing research and experience on the pros and cons of different ways of providing development assistance for health, the World Bank claims that it is challenging to link funding for health-systems directly to improvements in outcomes of a particular disease control effort.

Sarbib and colleagues also note that the World Bank in India focused on co-financing a country-led strategy that tailored drug-treatment policies to match different malaria parasites within different regions of the country. They write that this approach is more effective than a one-size-fits-all policy in a large country like India where patterns of drug sensitivity vary within the country itself. Sarbib and colleagues present evidence to show that reported malaria cases declined much faster in those project districts supported by the World Bank than in India as a whole.

Responding to Attaran and colleagues' calls for the Bank to hand over US$1 billion to the GFATM, Sarbib and colleagues state they are currently working in close cooperation with the Fund. The authors' stress the increased staffing and financing of malaria control by the Bank in their Viewpoint. They state: "World Bank Group President, Paul Wolfowitz, has put the full weight of his leadership behind the Bank's renewed commitment to malaria, with a strong emphasis on results."

In an accompanying Editorial The Lancet comments: "Malaria accounts for 10% of Africa's disease burden and US$12 billion yearly in lost productivity. The Abuja declaration of April 25, 2000, calls for halving malaria mortality in Africa by 2010. If the World Bank is serious about being judged on results, as Sarbib and colleagues propose, then the Abuja target provides an excellent opportunity for cost-effective action."
Contact: Professor Amir Attaran, Institute of Population Health, University of Ottawa, One Stewart Street, Ottawa, Ontario K1N 6NF, Canada. T) +1 613 562 5800 x2889 / +1 613 276 7687 (mobile)

Jean-Louis Sarbib, World Bank, 1818 H Street NW, Washington, DC 20433, USA. Press contact: Phil Hay (202) 473 1796

The Lancet press office T) 0207 424 4949/4249


Related Malaria Articles from Brightsurf:

Clocking in with malaria parasites
Discovery of a malaria parasite's internal clock could lead to new treatment strategies.

Breakthrough in malaria research
An international scientific consortium led by the cell biologists Volker Heussler from the University of Bern and Oliver Billker from the UmeƄ University in Sweden has for the first time systematically investigated the genome of the malaria parasite Plasmodium throughout its life cycle in a large-scale experiment.

Scientists close in on malaria vaccine
Scientists have taken another big step forward towards developing a vaccine that's effective against the most severe forms of malaria.

New tool in fight against malaria
Modifying a class of molecules originally developed to treat the skin disease psoriasis could lead to a new malaria drug that is effective against malaria parasites resistant to currently available drugs.

Malaria expert warns of need for malaria drug to treat severe cases in US
The US each year sees more than 1,500 cases of malaria, and currently there is limited access to an intravenously administered (IV) drug needed for the more serious cases.

Monkey malaria breakthrough offers cure for relapsing malaria
A breakthrough in monkey malaria research by two University of Otago scientists could help scientists diagnose and treat a relapsing form of human malaria.

Getting to zero malaria cases in zanzibar
New research led by the Johns Hopkins Center for Communication Programs, Ifakara Health Institute and the Zanzibar Malaria Elimination Program suggests that a better understanding of human behavior at night -- when malaria mosquitoes are biting -- could be key to preventing lingering cases.

Widely used malaria treatment to prevent malaria in pregnant women
A global team of researchers, led by a research team at the Liverpool School of Tropical Medicine (LSTM), are calling for a review of drug-based strategies used to prevent malaria infections in pregnant women, in areas where there is widespread resistance to existing antimalarial medicines.

Protection against Malaria: A matter of balance
A balanced production of pro and anti-inflammatory cytokines at two years of age protects against clinical malaria in early childhood, according to a study led by ISGlobal, an institution supported by ''la Caixa'' Foundation.

The math of malaria
A new mathematical model for malaria shows how competition between parasite strains within a human host reduces the odds of drug resistance developing in a high-transmission setting.

Read More: Malaria News and Malaria Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to